Dr. Naoto Hirano

Clinician Scientist I

Dr. Naoto Hirano’s research program aims to devise novel anti-tumor immunotherapeutic modalities that can cure cancer. Dr. Hirano’s research team is particularly interested in understanding how the interactions between T cells and antigen-presenting cells affect priming, expansion, persistence and differentiation of T cells, as well as how this leads to the subsequent generation and maintenance of anti-tumor T cell memory.

Current affiliations

  • Clinician Scientist I, OICR
  • Associate Director for Research, Tumour Immunotherapy Program, Princess Margaret Cancer Centre
  • Senior Scientist, Princess Margaret Cancer Centre
  • Professor of Medicine, Department of Immunology, University of Toronto

Research interests

  • Cancer immunotherapy
  • Adoptive T-cell therapy

Select publications

See Dr. Hirano’s recent publications on PubMed.

Previous experience and education

  • Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Related links

University Health Network Researcher Page – Dr. Naoto Hirano

Opportunities to collaborate

To collaborate with Dr. Hirano, please contact him directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.


Dr. Naoto Hirano